Chief Executive Emil Kakkis expressed disappointment, citing the discrepancy between the failed Aspire study and the promising data observed in earlier Phase 1/2 trials. The company is now reevaluating the entire apazunersen program and has signaled an immediate shift in corporate strategy to prioritize fiscal stability.

Management intends to implement significant expense reductions while pivoting focus toward the company's existing commercial business. Kakkis noted that Ultragenyx will prioritize expansion into new markets to reach profitability by next year, effectively sidelining development efforts that no longer align with its immediate financial goals.